Novartis announced plans to add a new active pharmaceutical ingredient manufacturing facility in Morrisville, North Carolina, as part of a US investment plan totaling $23 billion to expand manufacturing, research and development. The 56,200-square-foot site will enable end-to-end production for solid dosage tablets, capsules and RNA therapies, expanding the company’s US footprint to five sites across three locations. The move accompanies ongoing expansions, including a San Diego biomedical research center, a Denton RLT facility, and additional plants in Winter Park, Carlsbad and elsewhere, positioning the US as a hub for radioligand therapies and other future treatments. Vas Narasimhan, CEO, said the plan finalizes seven new facilities in the US and reinforces local development and delivery of medicines. The release notes forward-looking statements with usual caveats about regulatory, financial and macroeconomic risks, including pricing pressures and potential tariffs.
Novartis emphasizes its goal to manufacture its key medicines in the US for US patients and to broaden capabilities across small and large molecules, radioligand, RNA therapeutics and cell therapies.
← Atlas › News